Dojolvi (triheptanoin)
Lipids Oral Liquid (Ml)
Last reviewed · Source: First Databank (FDB) drug data
Overview
USES: This medication is used to treat certain inherited disorders (long-chain fatty acid oxidation disorders- LC-FAOD). People with LC-FAOD cannot break down certain nutrients (fatty acids) to use as energy due to the lack of certain enzymes. Triheptanoin is not a cure for LC-FAOD but is a medium-chain triglyceride that works by providing fatty acids and energy to the body.
Generic name: triheptanoin
Pronunciation: (trye-HEP-ta-noyn)
Drug class: Lipids
Therapeutic class: Electrolyte Balance-Nutritional Products
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Dojolvi
Indications
The following indications are listed for Dojolvi:
- Long-Chain Fatty Acid Oxidation Disorder
Also known as: Long Chain 3-Hydroxyacyl-Coa Dehydrogenase Deficiency, Long Chain 3-Hydroxyacyl-Coenzyme A Dehydrogenase Deficiency.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Triheptanoin/Orlistat
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Triheptanoin is hydrolyzed by pancreatic enzymes in the intestines to heptanoate and glycerol, which are then absorbed. Pancreatic lipase inhibitors (i.e., orlistat) can reduce the formation of heptanoate from triheptanoin.(1)
CLINICAL EFFECTS: Orlistat may reduce absorption of heptanoate, leading to insufficient supplementation of medium-chain fatty acids.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of triheptanoin states that concurrent use of pancreatic lipase inhibitors should be avoided.(1)
DISCUSSION: Orlistat may decrease exposure to the triheptanoin metabolite, heptanoate, and decrease the effectiveness of triheptanoin.(1)
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
- Exocrine pancreatic insufficiency
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
More Frequent
- Acute abdominal pain
- Diarrhea
- Nausea
- Vomiting
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Long-chain fatty acid oxidation disorder | ||
| E71.3 | ICD10CM | Disorders of fatty-acid metabolism |
| E71.30 | ICD10CM | Disorder of fatty-acid metabolism, unspecified |
| E71.31 | ICD10CM | Disorders of fatty-acid oxidation |
| E71.310 | ICD10CM | Long chain/very long chain acyl coA dehydrogenase deficiency |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.